R&D Pipeline

R&D Pipeline(In-House)

As of January 2020

Development
Stage

Development Code
(Generic name)

Development Classification Expected Indications
Category

Phase III

KPS-0373*
(Rovatirelin)
In-licensed /
Shionogi (Japan)

Spinocerebellar ataxia
- TRH receptor agonist -

AJM300
(Carotegrast Methyl)
In-licensed /
Co-development with EA Pharma (Japan)

Ulcerative colitis
- Alpha 4 integrin receptor antagonist -

CCX168
(Avacopan)
In-licensed /
Vifor-Fresenius Medical Care Renal Pharma (Switzerland)

Microscopic polyangiitis
Granulomatosis with polyangiitis
- Selective complement C5a receptor antagonist -

R788
(Fostamatinib)

In-licensed /
Rigel Pharmaceuticals (U.S.)

Chronic idiopathic thrombocytopenic purpura
- Tyrosine kinase inhibitor -

Phase II

KLH-2109
(Linzagolix)

Kissei

Endometriosis
- GnRH receptor antagonist -

MR13A9
(Difelikefalin)
In-licensed /
Co-development with Maruishi Pharmaceutical (Japan)

Uremic pruritus in dialysis patients
- Kappa opioid receptor agonist -

KDT-3594 Kissei

Parkinson's disease
- Dopamine receptor agonist -

Phase I / II YS110 In-licensed /
Y's AC, University of Tokyo, AMED (Japan)

Malignant mesothelioma
- Humanized anti-CD26 monoclonal antibody -


*: Phase III clinical trial has been completed and we are currently consulting with PMDA


R&D Pipeline(Out-Licensing)

As of January 2020

Development Stage Development Code /
Generic name
Development Company Territory Expected Indications
Category
NDA Mitiglinide Eisai(Japan) ASEAN *1 Type 2 diabetes mellitus
Silodosin Eisai(Japan) ASEAN, India, SriLanka *2 Dysuria associated with benign prostatic hyperplasia
Phase III KLH-2109
(Linzagolix)
ObsEva SA (Switzerland) Worldwide, except some countries in Asia such as Japan

Uterine fibroids
- GnRH receptor antagonist -

KLH-2109
(Linzagolix)
ObsEva SA (Switzerland) Worldwide, except some countries in Asia such as Japan

Endometriosis
- GnRH receptor antagonist -

Phase II Bedoradrine MediciNova(U.S.) Worldwide, except Japan

Acute exacerbation of asthma


*1: Launched in Thailand, the Philippines, Cambodia, Myanmar : Approved in Laos : NDA in Vietnam
*2: Launched in Thailand, India, Indonesia, the Philippines, Cambodia, Myanmar, Malaysia : NDA in 2 ASEAN countries